Teach me in 10

Teach me in 10: revealing the combinatorial power of genetic and epigenetic information for early cancer detection

In this Teach me in 10 episode we will explore how simultaneous sequencing of genetic and epigenetic bases in cfDNA allows for early cancer detection.
2:00 pm
 to 2:15 pm
 BST, 
27 April 2023
Teach me in 10

Teach me in 10: revealing the combinatorial power of genetic and epigenetic information for early cancer detection

In this Teach me in 10 episode we will explore how simultaneous sequencing of genetic and epigenetic bases in cfDNA allows for early cancer detection.
Originally presented on 27 April 2023.

About the webinar

In this Teach me in 10 episode we will explore how simultaneous sequencing of genetic and epigenetic bases in cfDNA allows for early cancer detection.

The development of high-throughput DNA sequencing has been key in illuminating cellular processes and understanding how variation and mutations play a role in disease states, such as cancer.

But it’s not just genetic sequences that control cellular fate and function – epigenetic modifications regulate gene expression in response to changes in behaviour or environment and play a key role in many biological processes. Variation in an individual’s genetic sequence will be associated with variation in DNA methylation that can functionally determine predisposition for disease. 

Advances in measuring both genetic and epigenetic variation in the context of the other is therefore important for revealing dynamic biological processes, allowing a more comprehensive view of cellular function. 

Learn more about how duet multiomics solution +modC, enables: 

  • Full genetic and epigenetic information in a single workflow 
  • Phased combined genetic and epigenetic marks 
  • Decreased limit of detection for low-frequency variant discovery 
  • Reduced consumption of sample and sequencing reagents, compared to multiple workflows for traditional NGS approaches

Stay up to date

Explore recent biomodal news and the events that we’ll be attending in the near future.

Cambridge Epigenetix is now biomodal